<DOC>
	<DOCNO>NCT00605566</DOCNO>
	<brief_summary>This phase II clinical trial ass efficacy combination metronomic cyclophosphamide tailor sorafenib dosing advance , progressive NET . NET highly vascular tumor , high VEGF expression correlate bad clinical pathological characteristic well poor prognosis . A novel antiangiogenic approach relies target endothelial cell also render sensitive VEGFR blockade achieve pericyte detachment . In study , dose sorafenib titrate maximum 800mg BID base patient ' toxicity novel pharmacodynamic assay measure inhibition molecular target ( PDGFR ) patient ' peripheral blood mononuclear cell . Dual VEGFR target achieve administer sorafenib plus metronomic low dose cyclophosphamide .</brief_summary>
	<brief_title>Efficacy Study Sorafenib Cyclophosphamide Treat Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm neuroendocrine tumor Progressive measurable metastatic disease Patients must disease currently amenable surgery Life expectancy great 3 month ECOG performance status â‰¤2 Patients must normal organ marrow function Negative pregnancy test ; agreement use adequate birth control Patients receive chemotherapy radiotherapy within last 4 week Patients receive Sorafenib advanced NET ( neuroendocrine tumor ) allow Any investigational agent within 4 week study Patients know brain metastasis History allergic reaction compound similar chemical/biologic composition sorafenib cyclophosphamide Concurrent cancer another primary site require treatment within past 3 year Uncontrolled intercurrent illness Pregnant woman woman breastfeed HIVpositive patient receive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Neuroendocrine</keyword>
	<keyword>sorafenib</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>